Geneva, Switzerland, February 2, 2024 – 20:00 CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO) (the “Company”), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, COVID long or post-COVID), announces that on February 2, 2024, the Autorité des marchés financiers (the “AMF”) approved an admission prospectus under number 24-016 (the “Prospectus”) in connection with the admission to trading on the regulated market of Euronext Paris of 4.666,901 new ordinary bearer shares of the Company issued following a capital increase of 5 million euros with cancellation of preferential subscription rights carried out as part of (i) an international private placement reserved for specialized and strategic investors of 4.666,901 new ordinary bearer shares (the “International Private Placement”) and (ii) a separate public offering to retail investors via the PrimaryBid platform in France of 95,004 new ordinary bearer shares (together with the International Private Placement, the “Offering”).
Français: https://geneuro.ch/data/news/Geneuro-CP-norme-de-mise-a-dispo-prospectus-02.02.2024.pdf